![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Massachusetts General Hospital Abbott Diabetes Care |
---|---|
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00694473 |
We hypothesize that measurements of interstitial fluid (ISF) glucose by the FreeStyle Navigator (Abbot Diabetes Care), a continuous glucose monitoring system, will correlate with blood glucose (BG) values in surgical and ICU patients with a clinically useful degree of accuracy.
Condition | Intervention |
---|---|
Critical Illness |
Device: Freestyle Navigator |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery |
Estimated Enrollment: | 250 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Freestyle Navigator: Experimental
Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
|
Device: Freestyle Navigator
Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
|
Critically ill patients treated with intensive insulin therapy will be monitored for up to 72 hours with the Freestyle Navigator continuous glucose monitor. The device display will be disabled so that continuous glucose monitoring results will not be available to care givers, although low (<60 mg/dL) and high (>250 mg/dL) threshold audio alarms will be enabled. Blood glucose monitoring will be performed according to the usual practice for patients treated with intensive insulin therapy in each intensive care unit, except that additional blood glucose measurements will be performed in response to Freestyle Navigator threshold alarm. All blood glucose management decisions will be made according to intensive insulin therapy protocol in each unit. Freestyle Navigator data will be downloaded from the device after each subject has completed the monitoring period. Blood glucose values obtained in the course of usual care, or in response to Freestyle Navigator threshold alarms, will be compared with time-matched Freestyle Navigator values to assess device accuracy and alarm sensitivity and specificity.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
In order to obtain adequate representation of patients with physiological alterations that might decrease correspondence between blood and ISF glucose, we will recruit 50 subjects in each of five groups:
United States, Massachusetts | |
Massachusetts General Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Contact: Robert Sutherlin, R.N. 617-724-6237 rsutherlin@partners.org | |
Sub-Investigator: David M. Nathan, M.D. | |
Sub-Investigator: Luca Bigatello, M.D. | |
Sub-Investigator: Arjun Rao, M.B.B.S. | |
Sub-Investigator: Guy Rordorf, M.D. | |
Sub-Investigator: Taylor Thompson, M.D. |
Principal Investigator: | Steven J. Russell, M.D., Ph.D. | Massachusetts General Hospital |
Responsible Party: | Massachusetts General Hospital ( Steven J. Russell ) |
Study ID Numbers: | 2007P-002178 |
Study First Received: | June 6, 2008 |
Last Updated: | June 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00694473 |
Health Authority: | United States: Institutional Review Board |
hyperglycemia hypoglycemia insulin critical illness intensive insulin therapy continuous glucose monitoring |
CGM interstitial fluid glucose intensive care unit Blood glucose Intensive insulin therapy |
Hyperglycemia Critical Illness Hypoglycemia Insulin |
Disease Attributes Pathologic Processes |